Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control gel Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

NCT03198728
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
SOV2012-F1, AndroGel
Drug
Lead sponsor
Marius Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT02786901
View directory record Official record
Conditions
Cataract, Pain, Ocular Inflammation
Interventions
Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants

NCT06511973
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline, A solution of 0.2% SLS
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 2Phase 3 Interventional

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

NCT03440359
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse
Drug · Diagnostic Test · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 23, 2026, 7:27 AM EDT
Not listed Phase 4 Interventional

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

NCT03082573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
Iraj Sabahi Research Inc.
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pleasanton, California • Turlock, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT01403116
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate, topical testosterone gel
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 2 Interventional

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

NCT00249782
View directory record Official record
Conditions
Rosacea
Interventions
Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 23, 2026, 7:27 AM EDT
Withdrawn Phase 2 Interventional

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 23, 2026, 7:27 AM EDT
Not listed Phase 3 Interventional

Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer

NCT00002659
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin-e therapeutic implant
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

NCT03680885
View directory record Official record
Conditions
ADHD, Controls
Interventions
Lidocaine gel, Placebo, Injected lidocaine
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris

NCT07469228
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Gel Microsphere, 0.04%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

NCT00653432
View directory record Official record
Conditions
Osteoarthritis
Interventions
Monovisc®, Saline
Device · Other
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

NCT00984971
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
Tenofovir, HEC Placebo, Open label tenofovir tablet
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 23, 2026, 7:27 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety Assessment of Experimental Bleaching Agents

NCT06802614
View directory record Official record
Conditions
Tooth Discoloration, Dentin Sensitivity, Patient Satisfaction
Interventions
BLEACHING GEL A, 5% NF_TiO2, BLEACHING GEL B, VISIBLE LIGHT IRRADIATION, Whiteness HP 35%, Whiteness HP Automixx 6%
Device · Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Topical Ibuprofen for Delayed Onset Mulscle Soreness

NCT01794923
View directory record Official record
Conditions
Pain
Interventions
IBU BID, Placebo BID, IBU TID, Placebo TID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

NCT03068780
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Oleogel-S10, Control gel
Drug
Lead sponsor
Amryt Research Limited
Industry
Eligibility
21 Days and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Aurora, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata

NCT00063076
View directory record Official record
Conditions
Alopecia Areata
Interventions
Targretin Gel 1%
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 23, 2026, 7:27 AM EDT
Not listed Not applicable Interventional

Umbilical Cord Care for the Prevention of Colonization

NCT01893060
View directory record Official record
Conditions
Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 7 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 23, 2026, 7:27 AM EDT
Not listed Phase 2 Interventional

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

NCT04759664
View directory record Official record
Conditions
EGFRI Induced Acneiform Lesions
Interventions
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Glendale, California • Santa Monica, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 4%, SB206 8%, SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
2 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Ana, California • Thornton, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 23, 2026, 7:27 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05852730
View directory record Official record
Conditions
Motion Sickness, Space, Motion Simulation, Parabolic Flight
Interventions
DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine)
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 23, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

INSIGHT, A Comprehensive, Multidisciplinary Brain Training System

NCT02780739
View directory record Official record
Conditions
Cognitive Ability, General
Interventions
Cognitive Training - 48 sessions, Fitness, Active Control, active tDCS, sham tDCS, Cognitive Training - 20 sessions
Behavioral · Device
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 44 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 23, 2026, 7:27 AM EDT